167 related articles for article (PubMed ID: 16358237)
1. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
[TBL] [Abstract][Full Text] [Related]
2. Anderson-Fabry disease in Austria.
Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
[TBL] [Abstract][Full Text] [Related]
3. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
4. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
5. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
Demontis R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: a treatable lysosomal storage disorder.
Phadke SR; Mandal K; Girisha KM
Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
[TBL] [Abstract][Full Text] [Related]
8. [CME. Fabry disease: rare but not to be missed].
Steinack C; Gaspert A; Kovacs R; Nowak A
Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
[No Abstract] [Full Text] [Related]
9. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
11. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
12. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].
Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R
Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649
[TBL] [Abstract][Full Text] [Related]
13. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
[TBL] [Abstract][Full Text] [Related]
14. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
Barbey F; Widmer U; Burnier M; Lidove O
Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
[TBL] [Abstract][Full Text] [Related]
15. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.
Hauser AC; Lorenz M; Sunder-Plassmann G
J Intern Med; 2004 Jun; 255(6):629-36. PubMed ID: 15147526
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
Ramaswami U
Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
19. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.
Whybra C; Kampmann C; Krummenauer F; Ries M; Mengel E; Miebach E; Baehner F; Kim K; Bajbouj M; Schwarting A; Gal A; Beck M
Clin Genet; 2004 Apr; 65(4):299-307. PubMed ID: 15025723
[TBL] [Abstract][Full Text] [Related]
20. [Fabry-Anderson disease: current state of knowledge].
Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]